Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540804 | 0.72 | CES1 (0.42) | CES1HTTACHEMLYCDPLA2G2D | |
| SCHEMBL8888411 | 0.72 | RAB9A (0.51) | CES1HTTRAB9A | |
| SCHEMBL15519140 | 0.66 | POLB (0.46) | CES1POLBAPEX1TDP1L3MBTL1 | |
| SCHEMBL6140412 | 0.65 | CES1 (0.35) | CES1ACHEMLYCDHDAC6 | |
| SCHEMBL4612810 | 0.64 | MLYCD (0.37) | CES1HTTACHEMLYCDHDAC6 | |
| SCHEMBL8539713 | 0.64 | POLB (0.41) | CES1HTTPOLBHDAC6CA2 | |
| SCHEMBL4611671 | 0.62 | MLYCD (0.40) | HTTACHEMLYCD | |
| SCHEMBL4612812 | 0.62 | NR1H2 (0.39) | HTTMLYCDCA2RAB9A | |
| SCHEMBL9765616 | 0.62 | CNR2 (0.47) | HTTPOLBMLYCDMAPK1RAB9A | |
| SCHEMBL13278800 | 0.61 | MAPT (0.39) | L3MBTL1CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | claimed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | CES1 3682/4885HTT 1615/4885ACHE 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.